Loading clinical trials...
Loading clinical trials...
Prospective, Multinational, Non-interventional Post-authorisation Study to Document the Long-term Immunogenicity, Safety, and Efficacy of Human-cl rhFVIII (Simoctocog Alfa) in Patients With Haemophilia A Treated in Routine Clinical Practice
Conditions
Locations
39
United States
University of Florida
Gainesville, Florida, United States
Nicklaus Children's Hospital
Miami, Florida, United States
Tulane University
New Orleans, Louisiana, United States
Hemophilia Treatment Center of Nevada
Las Vegas, Nevada, United States
Gulf States Hemophilia and Thrombophilia
Houston, Texas, United States
Centro de Tratamiento de la Hemofilia Cordoba
Córdoba, Argentina
Start Date
January 1, 2015
Primary Completion Date
August 20, 2020
Completion Date
August 20, 2020
Last Updated
October 21, 2021
NCT07226206
NCT05987449
NCT04645199
NCT06703606
NCT06702579
NCT03818763
Lead Sponsor
Octapharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions